期刊文献+

淀粉样蛋白膜内片段的AD相关生物学特性研究 被引量:2

Research on the Biological Characteristics of Intramembranous Fragments of Amyloid-β Related with AD
原文传递
导出
摘要 目的:体外条件下研究淀粉样蛋白膜内片段(intramembranous fragments of amyloid-β,IF-Aβ)对Aβ42成纤维和神经毒性的影响。方法:(1)硫磺素T法检测IF-Aβ对Aβ42成纤维性的影响;(2)MTT法和荧光分光光度计检测IF-Aβ对经过Aβ42预处理的体外培养神经元的活性和胞浆钙离子浓度影响。结果:(1)IF-Aβ本身无成纤维性,而且可以抑制或解聚Aβ42成纤维;(2)相对于单独经Aβ42预处理的体外培养神经元,IF-Aβ的加入可以提高神经元的活性和降低胞浆钙离子的浓度。结论:IF-Aβ具有保护体外培养神经元免受Aβ42毒性作用的功能,为阿尔茨海默病(Alzheimer's disease,AD)的在体治疗研究奠定了基础。 Objective: To study the effect of intramembranous fragments of amyloid- (IF-A) on fibroplastic and neurotoxic activities of AI342 in vitro. Methods: Thioflavin T was applied to detect IF-A effect on A1342 assembly. The biological activity of the IF-A was assessed by the CellTiter 96 Cell Proliferation Assay (MTT assay). The calcium ion concentration in cell were also detected, as well as the mixtures ofA1342: IF-A. Results: (1) IF-A showed no aggregation at concentrations up to 750 p,M but substantial inhibition to AI342 fibril growth; (2)Compared with the in vitro cultured neuron which were treated only by AI342, that treated by IF-AI3 and A1342 (at a 1:1 concentration ratio) showed an increased activities and a decreased calcium ion concentration. Conclusion: IF-A could protect neuron viability from toxic damage by AI342 in vitro. It provides a foundation for the clinical treatment of Alzheimer's disease/n v/vo.
出处 《现代生物医学进展》 CAS 2012年第21期4023-4026,共4页 Progress in Modern Biomedicine
基金 国家高技术研究发展计划(863计划)课题(2007AA021901) 湖南省自然科学基金(08JJ3073) 河南省重点科技攻关项目(102102310327)
关键词 淀粉样蛋白 阿尔茨海默病 生物学特性 Amyloid Alzheimer'deasease Biology characteristics
  • 相关文献

参考文献21

  • 1Price DL, Sisodia SS. Cellular and molecular biology of Alzheimer's disease and animal models[J]. Annu Rev Med, 1994, 45:435-446.
  • 2Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics [J]. Science, 2002, 297(5580): 353-356.
  • 3Salloway S, Mintzer J, Weiner MF, et al. Disease-modifying therapies in Alzheimer's disease[J]. Alzheimers Dement, 2008, 4(2): 65-79.
  • 4马志红,徐淑梅.H102对Aβ42致神经元毒性的保护作用[J].天津医药,2008,36(3):198-200. 被引量:5
  • 5李光武,汪华侨,姚志彬.FT-IR光谱法研究TA9902抑制Aβ_(1-42)聚集的分子机制[J].中国病理生理杂志,2006,22(1):84-87. 被引量:3
  • 6Soto C, Sigurdsson EM, Morelli L, et al. B-sheet breaker peptides in- hibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy[J]. Nat Meal, 1998, 4(7): 822-826.
  • 7Sigurdsson EM, Scholtzova H, Mehta PD, et al. Immunization with a non-toxic/non-fibrillar amyloid-~ homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice [J]. Am J Pathol, 2001, 159(2): 439-447.
  • 8Zameer A, Schulz P, Wang MS, et al. Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42 [J]. Biochemistry, 2006, 45(38): 11532-11539.
  • 9Lansbury Jr P T. Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease [J]. CkLrrent Opinion in Chemical Biology, 1997, 1(2): 260-267.
  • 10Hilbich C, Kisters-woike B, Reed J, et al. Substitutions of hydropho- bic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides[J]. J Mol Biol, 1992, 228(2): 460-473.

二级参考文献17

  • 1Kallijarvi J,Haltia M,Baumann MH.Amphoterin includes a sequence motif which is homologous to the Alzheimer' s beta-amyloid peptide (A beta),forms amyloid fibrils in vitro,and binds avidly to A beta[J].Biochemistry,2001,40(34):10032-10037.
  • 2Hong L,Koelsch G,Lin X,et al.Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor[J].Science,2000,290(5489):150-153.
  • 3Serpell LC,Blake CC,Fraser PE.Molecular structure of a fibrillar Alzheimer' s A beta fragment [ J].Biochemistry,2000,39(43):13269-13275.
  • 4Burdick D,Soreghan B,Kwon M,et al.Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs[J].J Biol Chem,1992,267(1):546-554.
  • 5Soto C,Castano EM.The conformation of Alzheimer' s beta peptide determines the rate of amyloid formation and its resistance to proteolysis[J].Biochem J,1996,314(Pt2):701-709.
  • 6Susi H,Byler DM.Resolution-enhanced Fourier transform infrared spectroscopy of enzymes [ J ].Methods Enzymol,1986,130(2):290-311.
  • 7Krimm S,Bandekar J.Vibrational analysis of peptides,polypeptides,and proteins.V.Normal vibrations of betaturns[J].Biopolymers,1980,19(1):1-6.
  • 8Inouye H,Fraser PE,Kirschner DA.Structure of β-crystallite assemblies formed by Alzheimer β-amyloid protein analogues analysis by X-ray diffraction[J].Biophys J,1993,64(3):502-519.
  • 9Miyakawa T,Katsuragi S,Watanabe K,et al.Ultrastruaural studies of amyloid fibrils and senile plaques in human brain[J].Acta Neuropath,1986,70(2):202-208.
  • 10Goldsbury C,Goldie K,Pellaud J,et al.Amyloid fibril formation from full-length and fragments of amylin[J].J Struct Biol,2000,130(2-3):352-356.

共引文献6

同被引文献24

  • 1朱玉德,黄强.起源细胞分化障碍与胶质瘤发生的分子关系[J].实用肿瘤杂志,2005,20(1):81-84. 被引量:9
  • 2李国营,汪华侨,胡金家,林贤,徐杰,姚志彬.Aβ亚单位疫苗接种Tg2576鼠对脑内淀粉样斑块沉积和行为学的影响[J].解剖学报,2006,37(1):6-11. 被引量:7
  • 3Schenk D, Barbour R, Dunn W, et al. Immunization withamyloid-beta attenuates Alzheimer-disease-like pathologyin the PDAPP mouse[J|. Nature, 1999,400(6740): 173-177.
  • 4Janus C, Pearson J, Mclaurin J,et al. A beta peptideimmunization reduces behavioural impairment and plaquesin a model of Alzheimer,s diseaseP} Nature, 2000,408 (6815):979-982.
  • 5Wisniewski T,Konietzko U. Amyloid—beta immunisation forAlzheimer,s disease[J]. Lancet Neurol, 2008, 7(9): 805-811.
  • 6Zameer A, Schulz P, Wang MS,et al. Single chain Fvantibodies against the 25 -35 Abeta fragment inhibitaggregation and toxicity of Abeta42[J]. Biochemistry, 2006,45(38): 11532-11539.
  • 7Demattos RB, Bales KR,Cummins DJ, et al. Peripheralanti —A beta antibody alters CNS and plasma A betaclearance and decreases brain A beta burden in a mousemodel of Alzheimer's disease[J]. Proc Natl Acad Sci USA,2001,98(15): 8850-8855.
  • 8Demattos RB, Bales KR, Cummins DJ, et al. Brain toplasma amyloid -beta efflux: a measure of brain amyloidburden in a mouse model of Alzheimer's disease [J].Science, 2002, 295(5563): 2264-2267.
  • 9Demattos RB, Bales KR, Parsadanian M, et al. Plaque -associated disruption of CSF and plasma amyloid (Ap)equilibrium in a mouse model of Alzheimer,s diseasefj]. JNeurochem, 2002,81(2): 229-236.
  • 10Lemere CA, Spooner ET, LaFrancois J, et al. Evidence forperipheral clearance of cerebral Ap protein followingchronic, active Ap immunization in PS APP mice [J].Neurobiol Dis, 14 (1): 10-18.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部